Medication-Assisted Weight Loss
The global use of GLP-1 and GIP receptor agonists, including Semaglutide (Ozempic®, Wegovy®), Tirzepatide (Mounjaro®, Zepbound™), and the orally administered Rybelsus®, has surged, leading to their inclusion in the FDA’s Drug Shortage List. This increase in demand has prompted the FDA to guide compounding pharmacies in creating essential alternatives for these patented drugs during the shortage period. SRx Compounding & Wellness has both the injectable and sublingual versions available. We can discuss with you and your provider which option may be best for you.
How Does it Work?
GLP-1 and GIP receptor agonists aid in managing blood sugar levels by enhancing insulin release in response to food, reducing the liver’s glucose production, and decelerating stomach emptying post-meals. These effects help in blood glucose regulation, promote a feeling of fullness, and support gradual weight loss. These medications are recommended alongside diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus and are not advised for type 1 diabetes patients.
Compounded Non-Injection Option
SRx Compounding & Wellness offers a unique solution by compounding Semaglutide into a sublingual form. This alternative is particularly appealing for those seeking to avoid injections and the challenges associated with storing these medications. The sublingual form may also mitigate common side effects such as nausea and headaches. Our specially formulated sublingual suspension comes in a convenient bottle with an oral syringe for accurate dosing.
Injectable Options
To best care for our patients, we also offer injectable Semaglutide. The injection is done once a week in the thigh, stomach, or arm. The doses have a short expiration date and must be refrigerated.
Interested in learning more, please reach out to SRx Compounding & Wellness. Our team is ready to discuss your needs!
